• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.

作者信息

Ray A, Das D S, Song Y, Hideshima T, Tai Y-T, Chauhan D, Anderson K C

机构信息

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

出版信息

Leukemia. 2018 Mar;32(3):843-846. doi: 10.1038/leu.2017.322. Epub 2017 Nov 6.

DOI:10.1038/leu.2017.322
PMID:29104288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5842120/
Abstract
摘要

相似文献

1
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.新型组蛋白去乙酰化酶6（HDAC6）抑制剂ACY-241与抗程序性死亡配体1（PD-L1）抗体联合使用可增强多发性骨髓瘤的抗肿瘤免疫力和细胞毒性。
Leukemia. 2018 Mar;32(3):843-846. doi: 10.1038/leu.2017.322. Epub 2017 Nov 6.
2
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.α-烯醇化酶（ENO1）作为多发性骨髓瘤新型免疫代谢靶点的临床前验证。
Oncogene. 2020 Mar;39(13):2786-2796. doi: 10.1038/s41388-020-1172-0. Epub 2020 Feb 5.
3
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.1类组蛋白去乙酰化酶（HDAC）和HDAC6抑制通过干扰素-α和全反式维甲酸（ATRA）反向调节骨髓瘤细胞中CD38的诱导。
Br J Haematol. 2019 Jun;185(5):969-974. doi: 10.1111/bjh.15673. Epub 2018 Nov 26.
4
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.利洛司他联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤：首个选择性组蛋白去乙酰化酶 6 抑制剂
Clin Cancer Res. 2017 Jul 1;23(13):3307-3315. doi: 10.1158/1078-0432.CCR-16-2526. Epub 2017 Jan 4.
5
Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.多发性骨髓瘤患者中组蛋白去乙酰化酶抑制剂相关不良事件的优化管理：以帕比司他为重点
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):501-507. doi: 10.1016/j.clml.2018.05.007. Epub 2018 May 24.
6
HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.HDAC6 抑制剂 ACY-1215 通过增强 STAT1 乙酰化来阻断 PD-L1 用于结直肠癌免疫治疗。
Cancer Immunol Immunother. 2024 Jan 17;73(1):7. doi: 10.1007/s00262-023-03624-y.
7
The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.抗 PD-1/PD-L1 抗体联合化疗或 CTLA4 抗体作为晚期肺癌一线治疗的疗效和安全性。
Int J Cancer. 2018 Jun 1;142(11):2344-2354. doi: 10.1002/ijc.31252. Epub 2018 Jan 25.
8
Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.抗 CD137 和 PD-1/PD-L1 抗体走向临床协同作用。
Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.
9
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.PD-1/PD-L1 抑制剂在多发性骨髓瘤中的研究进展。
Front Immunol. 2018 Nov 16;9:2431. doi: 10.3389/fimmu.2018.02431. eCollection 2018.
10
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.新型 HDAC6 抑制剂上调多发性骨髓瘤细胞 CD38 表达属类效应，并增强达雷妥尤单抗的疗效。
Leukemia. 2021 Jan;35(1):201-214. doi: 10.1038/s41375-020-0840-y. Epub 2020 Apr 29.

引用本文的文献

1
Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies.组蛋白去乙酰化酶抑制剂在癌症治疗中的潜在风险及可行的联合治疗策略。
World J Clin Oncol. 2025 Aug 24;16(8):108768. doi: 10.5306/wjco.v16.i8.108768.
2
HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy.ITF3756对HDAC6的抑制作用调节PD-L1表达和单核细胞表型：对一种有前景的免疫检查点阻断联合治疗的见解
Front Immunol. 2025 May 13;16:1546939. doi: 10.3389/fimmu.2025.1546939. eCollection 2025.
3
Treatment of multiple myeloma: What is the impact on T-cell function?

本文引用的文献

1
Checking in: T cells against multiple myeloma.
Blood. 2017 Sep 7;130(10):1175-1176. doi: 10.1182/blood-2017-05-783647.
2
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.帕博利珠单抗、泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤。
Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.
3
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.组蛋白去乙酰化酶与溴结构域联合抑制在非小细胞肺癌中的协同免疫刺激作用及治疗益处
多发性骨髓瘤的治疗：对T细胞功能有何影响？
Ther Adv Hematol. 2024 May 7;15:20406207241245194. doi: 10.1177/20406207241245194. eCollection 2024.
4
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.一种新型的 CD73 小分子抑制剂触发免疫介导的多发性骨髓瘤细胞死亡。
Blood Cancer J. 2024 Apr 9;14(1):58. doi: 10.1038/s41408-024-01019-5.
5
Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer.组蛋白去乙酰化酶6及组蛋白去乙酰化酶6抑制在结直肠癌中的作用
Pharmaceutics. 2023 Dec 29;16(1):54. doi: 10.3390/pharmaceutics16010054.
6
Exploring the sonodynamic effects of bacteriochlorophyll a.探索细菌叶绿素a的声动力效应。
Front Bioeng Biotechnol. 2023 May 11;11:1186897. doi: 10.3389/fbioe.2023.1186897. eCollection 2023.
7
Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma.发现新型苯甲脒基组蛋白去乙酰化酶 6（HDAC6）抑制剂，具有增强黑色素瘤抗 PD-L1 免疫治疗的作用。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2201408. doi: 10.1080/14756366.2023.2201408.
8
Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer.新型 LSD1/HDAC6 双重抑制剂治疗癌症。
PLoS One. 2023 Jan 3;18(1):e0279063. doi: 10.1371/journal.pone.0279063. eCollection 2023.
9
HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells.HDAC8 选择性抑制剂 PCI-34051 增强 ACY-241 对卵巢癌细胞的抗癌作用。
Int J Mol Sci. 2022 Aug 3;23(15):8645. doi: 10.3390/ijms23158645.
10
Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases.选择性组蛋白去乙酰化酶6抑制剂ACY-1215在癌症及其他人类疾病中的作用
Front Pharmacol. 2022 May 16;13:907981. doi: 10.3389/fphar.2022.907981. eCollection 2022.
Cancer Discov. 2017 Aug;7(8):852-867. doi: 10.1158/2159-8290.CD-16-1020. Epub 2017 Apr 13.
4
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.里西利司他联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的多中心 1b 期试验。
Lancet Oncol. 2016 Nov;17(11):1569-1578. doi: 10.1016/S1470-2045(16)30375-8. Epub 2016 Sep 17.
5
Essential role of HDAC6 in the regulation of PD-L1 in melanoma.组蛋白去乙酰化酶6（HDAC6）在黑色素瘤中对程序性死亡受体配体1（PD-L1）调控中的关键作用。
Mol Oncol. 2016 May;10(5):735-750. doi: 10.1016/j.molonc.2015.12.012. Epub 2016 Jan 6.
6
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.组蛋白去乙酰化酶抑制上调黑色素瘤中程序性死亡受体1配体并增强程序性死亡受体1阻断免疫疗法。
Cancer Immunol Res. 2015 Dec;3(12):1375-85. doi: 10.1158/2326-6066.CIR-15-0077-T. Epub 2015 Aug 21.
7
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.选择性组蛋白去乙酰化酶6（HDAC6）抑制剂ACY-1215与硼替佐米对蛋白质降解途径的双重靶向作用在淋巴瘤中具有协同效应。
Clin Cancer Res. 2015 Oct 15;21(20):4663-75. doi: 10.1158/1078-0432.CCR-14-3068. Epub 2015 Jun 26.
8
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.来那度胺增强免疫检查点阻断诱导的多发性骨髓瘤免疫反应。
Clin Cancer Res. 2015 Oct 15;21(20):4607-18. doi: 10.1158/1078-0432.CCR-15-0200. Epub 2015 May 15.
9
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.瑞克林司他（ACY-1215）诱导的聚集物形成抑制加速了卡非佐米诱导的多发性骨髓瘤细胞死亡。
Br J Haematol. 2015 May;169(3):423-34. doi: 10.1111/bjh.13315. Epub 2015 Feb 23.
10
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.